Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 5Sarcoma 1Myeloid 1CNS 1

Conditions

Rhabdomyosarcoma 1

Interventions

Radiotherapy 35Doxorubicin 30Ifosfamide 29Cyclophosphamide 24Vincristine 23Filgrastim 23Etoposide 20Temozolomide 14Granulocyte Colony-Stimulating Factor 14Dactinomycin 11Cisplatin 11Trabectedin 10Methotrexate 10Gene Expression Profiling 10Radiation 9Imatinib Mesylate 9Surgical Procedures, Operative 8Polymerase Chain Reaction 8Irinotecan 8Specimen Handling 7Paclitaxel 7Chemotherapy, Adjuvant 7Mesna 6Immunohistochemistry 6Gemcitabine 6Carmustine 6Biopsy 6sargramostim 5pegfilgrastim 5etoposide phosphate 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Spinal Puncture × Sarcoma × Clear all
NCT07466316 2026-03-12

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Children's Oncology Group

Phase 3 Not yet recruiting
342 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡